Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics develops investigational therapies for immune-mediated diseases, with news centered on its RASP modulator platform and late-stage ocular programs. Company updates commonly cover reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa; and next-generation RASP modulators including ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases.
Recurring developments include FDA interactions on the reproxalap New Drug Application, clinical and preclinical results, pipeline prioritization, manufacturing and regulatory disclosures, and research-and-development presentations. Aldeyra also reports conference participation and corporate updates tied to its Nasdaq-listed biotechnology issuer profile.
Aldeyra Therapeutics (Nasdaq: ALDX) has received Orphan Designation from the European Medicines Agency (EMA) for ADX-2191, a novel intravitreal methotrexate injection designed to treat primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma.
The rare cancer affects 100-200 people annually in the European Union and currently has no approved treatment. A planned clinical trial, approved via Special Protocol Assessment, will evaluate cancer cell clearance in up to 20 patients, comparing single versus eight intraocular injections of ADX-2191. The trial is set to begin in H2 2025 and conclude in 2026.
The EMA's Orphan Designation provides benefits including reduced fees, protocol assistance, and up to 10 years of market exclusivity in the EU.
Aldeyra Therapeutics (NASDAQ:ALDX) has received FDA Fast Track designation for ADX-2191, its intravitreal methotrexate injection treatment for retinitis pigmentosa. This rare genetic eye disease, affecting over 1 million people worldwide, currently has no approved treatments for most forms.
The designation follows positive Phase 2 clinical trial results announced in 2023, which showed improvements in retinal sensitivity. Aldeyra plans to initiate a Phase 2/3 clinical trial in 2025. The Fast Track status, combined with previous Orphan Drug Designation, enables frequent FDA interactions and potential expedited review processes.
Aldeyra Therapeutics (NASDAQ:ALDX), a biotechnology company focused on immune-mediated and metabolic diseases, has announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. The company's President and CEO, Todd C. Brady, M.D., Ph.D., will engage in a fireside chat with Matthew Caufield, Director of Equity Research at H.C. Wainwright & Co., on August 13, 2025, at 10:30 a.m. ET. The discussion will be accessible via webcast through Aldeyra's investor relations website and will remain available for 90 days after the event.
Aldeyra Therapeutics (NASDAQ:ALDX) announced that its ADX-2191 (methotrexate intravitreal injection) has received Orphan Designation from the European Medicines Agency (EMA) for treating inherited retinal dystrophies, including retinitis pigmentosa. This designation follows a previous Orphan Drug Designation from the FDA.
The treatment targets retinitis pigmentosa, a rare genetic eye disease affecting over 1 million people worldwide with no currently approved drug treatments. A Phase 2 clinical trial in 2023 showed improvements in retinal sensitivity. The company plans to initiate a Phase 2/3 clinical trial in 2025.
The EMA's Orphan Designation provides benefits including reduced regulatory fees, clinical protocol assistance, research grants, and up to 10 years of market exclusivity in the EU.
Aldeyra Therapeutics (Nasdaq: ALDX) announced that the FDA has accepted its resubmitted New Drug Application (NDA) for reproxalap, a first-in-class drug candidate for dry eye disease treatment. The FDA has set a PDUFA target action date of December 16, 2025.
The NDA resubmission included results from an additional clinical trial that successfully met its primary endpoint of reducing ocular discomfort compared to vehicle control. Notably, reproxalap is positioned as the only dry eye disease investigational therapy demonstrating acute activity in reducing both ocular discomfort and redness in pivotal trials that simulate disease flares.
Aldeyra Therapeutics (NASDAQ:ALDX) has received a Special Protocol Assessment Agreement Letter from the FDA for ADX-2191, a novel methotrexate formulation designed for intraocular injection to treat primary vitreoretinal lymphoma (PVRL). The company plans to conduct a clinical trial comparing single versus eight intraocular injections in up to 20 patients, measuring cancer cell clearance after 30 days.
Following a Complete Response Letter in June 2023 stating insufficient literature evidence, the FDA has agreed that a single clinical trial plus literature references will support NDA resubmission. The trial is expected to begin in H2 2025 and conclude in 2026. ADX-2191 aims to provide a reduced injection volume compared to current off-label compounded methotrexate treatments for this rare and potentially fatal cancer.
Aldeyra Therapeutics (NASDAQ: ALDX) has scheduled a conference call and webcast for Tuesday, May 6, 2025, at 8:00 a.m. ET to present topline results from its Phase 3 clinical trials of reproxalap for dry eye disease. The event will be accessible to domestic callers at (833) 470-1428 and international callers at (404) 975-4839, using access code 127477. A live audio webcast will be available through the "Investors & Media" section of Aldeyra's website and will remain archived for 90 days after the event.